- Summarizing the Intentions and Outcomes of JUO 2023 Issue 3
-
Kwak C
- KMID: 2553950
- J Urol Oncol.
- 2023 Nov;21(3):181-182.
- doi: 10.22465/juo.23edi004
-
- CITED
-
- Close
- SHARE
-
- Close
- Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
-
Wee CW, Cho J
- KMID: 2553954
- J Urol Oncol.
- 2023 Nov;21(3):217-227.
- doi: 10.22465/juo.234600560028
Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose. However, recent... -
- CITED
-
- Close
- SHARE
-
- Close
- The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
-
Ha H, Lim JH
- KMID: 2553953
- J Urol Oncol.
- 2023 Nov;21(3):208-216.
- doi: 10.22465/juo.234600540027
Renal cell carcinoma (RCC) remains a significant challenge in oncology, prompting thorough investigations into adjuvant treatments aimed at enhancing both survival and quality of life for patients. In this review,... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
-
Yu J, Sung HH
- KMID: 2553955
- J Urol Oncol.
- 2023 Nov;21(3):228-240.
- doi: 10.22465/juo.234600420021
Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) poses a significant clinical challenge, prompting a need for effective treatment options. Although radical cystectomy is a standard approach, it is burdened by... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer
-
Ku JY, Huda MN, Hwang EC, Lee CH, Kim KH, Kwon DD, Ha HK
- KMID: 2553961
- J Urol Oncol.
- 2023 Nov;21(3):277-277.
- doi: 10.22465/juo.err.kjuo.2022.20.1.52
-
- CITED
-
- Close
- SHARE
-
- Close
- Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
-
Lee CU, Song W, Kang M, Sung HH, Jeon HG, Seo SI, Jeon SS, Park SH, Jeong BC
- KMID: 2553956
- J Urol Oncol.
- 2023 Nov;21(3):241-248.
- doi: 10.22465/juo.234600620031
Purpose: Radical cystectomy (RC) is recommended for patients with non–muscle-invasive bladder cancer (NMIBC) who are unresponsive to intravesical bacillus Calmette-Guérin (BCG) instillation. However, RC is a very risky treatment, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
-
Nicaise EH, Schmeusser BN, Shah YB, Bilen MA, Ogan K, Master VA
- KMID: 2553951
- J Urol Oncol.
- 2023 Nov;21(3):183-199.
- doi: 10.22465/juo.234600500025
The purpose of this review is to provide an up-to-date understanding of the literature describing the impact of body composition on renal cell carcinoma (RCC) prognosis and outcomes. Although obesity... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
-
Kim S, Rho BY, Kang DH, Chung DY
- KMID: 2553959
- J Urol Oncol.
- 2023 Nov;21(3):264-270.
- doi: 10.22465/juo.234600520026
Purpose: In present, the use of androgen receptor targeting agents (ARTA) is one of the standard treatments for metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy. However, some patients may... -
- CITED
-
- Close
- SHARE
-
- Close
- Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
-
Kim TH, Choo SH, Shim KH, Kim SI
- KMID: 2553960
- J Urol Oncol.
- 2023 Nov;21(3):271-276.
- doi: 10.22465/juo.234600440022
Purpose: We propose a new potential marker of progression-free survival (PFS) called negative delta-prostate-specific antigen (PSA) time ratio (NDPSATR) and compare it with conventional PSA response, defined as PSA decline... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
Cho J, Suh J, You D, Jeong IG, Hong JH, Ahn H, Lim B
- KMID: 2553958
- J Urol Oncol.
- 2023 Nov;21(3):257-263.
- doi: 10.22465/juo.234604600023
Purpose: This study aimed to identify predictive factors for the response to abiraterone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods: This study analyzed the clinical characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
-
Lee DB, Kim JY, Lee YH, Song WH, Lee SS, Park SW, Nam JK
- KMID: 2553957
- J Urol Oncol.
- 2023 Nov;21(3):249-256.
- doi: 10.22465/juo.234600400020
Purpose: The efficacy of standard chemotherapy or radical cystectomy in patients who have urothelial tumors with variant histology (VH) is very limited in terms of their prognosis. This study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
-
Noh J, Song SH, Jung G, Lee S, Hong SK, Byun SS, Kim JK
- KMID: 2553952
- J Urol Oncol.
- 2023 Nov;21(3):200-207.
- doi: 10.22465/juo.234600480024
Purpose: This study investigated the effects of preoperative renal artery embolization (PRAE) before radical nephrectomy (RN) for advanced nonmetastatic renal cell carcinoma (RCC) on perioperative and oncologic outcomes. Materials and Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
